Fucis 150 mg tablets, No. 2

In stock: 14
$52.00

Composition

Active ingredient: fluconazole;

1 tablet contains 50 mg, 100 mg, 150 mg, or 200 mg of fluconazole;

Inactive ingredients: lactose monohydrate, microcrystalline cellulose, povidone KZ0, talc, magnesium stearate, sodium starch glycolate (type A), croscarmellose sodium.

Dosage Form

Tablets.

Main physical and chemical properties: white, round tablets with beveled edges and a score line on one side.

Pharmacotherapeutic group

Antifungal agents for systemic use. Triazole derivatives. ATC code J02A C01.

Pharmacological properties

Pharmacodynamics.

Mechanism of action.

Fluconazole is an antifungal agent of the triazole class. Its primary mechanism of action is the inhibition of the cytochrome P450-mediated demethylation of 14-alpha-lanosterol, which is an essential step in the biosynthesis of fungal ergosterol. The accumulation of 14α-methylsterols correlates with the subsequent loss of ergosterol through the fungal cell membrane and may account for the antifungal activity of fluconazole. Fluconazole is more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P450 enzyme systems.

Administration of fluconazole at a dose of 50 mg daily for 28 days does not affect plasma testosterone levels in men or endogenous steroid levels in women of reproductive age. Fluconazole at doses of 200–400 mg per day has no clinically significant effect on endogenous steroid levels or on the response to ACTH stimulation in healthy male volunteers.

A drug interaction study with antipyrine demonstrated that a single or repeated dose of 50 mg of fluconazole does not affect the metabolism of antipyrine.

In vitro susceptibility.

In vitro, fluconazole exhibits antifungal activity against the most common Candida species (including Candida albicans, Candida parapsilosis, and Candida tropicalis). Candida glabrata exhibits a wide range of susceptibility to fluconazole, whereas Candida krusei is resistant to it.

Fluconazole also demonstrates in vitro activity against both Cryptococcus neoformans and Cryptococcus gattii, as well as against the endemic molds Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and Paracoccidioides brasiliensis.

Relationship between pharmacokinetic and pharmacodynamic properties.

According to the results of animal studies, there is a correlation between the minimum inhibitory concentration (MIC) and efficacy against experimental models of mycoses caused by Candida species. According to the results of clinical studies, there is a linear relationship between AUC and the dose of fluconazole (approximately 1:1). There is also a direct, but insufficient, relationship between AUC or dose and a positive clinical response to treatment of oral candidiasis and, to a lesser extent, candidemia. Similarly, treatment of infections caused by strains against which fluconazole exhibits a high MIC is less satisfactory.

Mechanism of resistance.

Microorganisms of the genus Candida exhibit numerous mechanisms of resistance to azole antifungals. Fluconazole exhibits high MICs against fungal strains possessing one or more resistance mechanisms, which negatively impacts efficacy in vivo and in clinical practice. In normally susceptible Candida species, the most common mechanism of resistance development involves azole-targeted enzymes responsible for ergosterol biosynthesis. Resistance may also result from mutation, increased enzyme production, drug efflux mechanisms, or the development of compensatory pathways.

Cases of Candida spp. superinfection caused by species other than Candida albicans have been reported; these species are often resistant to fluconazole (e.g., Candida krusei, C. auris). Alternative antifungal agents should be used to treat such cases. The mechanisms of resistance have not been fully elucidated in some naturally resistant Candida species (C. krusei) or species with acquired resistance (C. auris).

Breakpoints (in accordance with the recommendations of the European Committee on Antimicrobial Susceptibility Testing).

Based on an analysis of pharmacokinetic/pharmacodynamic data, in vitro susceptibility, and clinical response, breakpoints for fluconazole against microorganisms of the genus Candida were established. These have been categorized into species-unrelated breakpoints, which were primarily determined based on pharmacokinetic/pharmacodynamic information and are independent of species-specific minimum inhibitory concentration (MIC) values, and species-specific breakpoints, which are most commonly associated with infections in humans. These breakpoints are listed below.

Antifungal Agent Species-specific cut-off values

S ≤ / R >

Species-unrelated breakpoints

S ≤ / R >

Candida albicans Candida glabrata Candida krusei Candida parapsilosis Candida tropicalis
Fluconazole 2/4 IE
  • -
2/4 2/4 2/4

S = sensitive;

R = resistant;

a – control points not specific to a particular species, which were largely determined based on pharmacokinetic/pharmacodynamic information and do not depend on species-specific minimum inhibitory concentration (MIC) values. They were studied only in microorganisms for which no specific reference point exists;

  • susceptibility testing is not recommended because this species is not a target for drug therapy;

IE – there is insufficient evidence to determine whether this species is a target for drug therapy.

Pharmacokinetics.

The pharmacokinetic properties of fluconazole are similar following intravenous and oral administration.

Absorption.

Fluconazole is well absorbed following oral administration, and plasma concentrations and systemic bioavailability exceed 90% of the plasma concentrations of fluconazole achieved following intravenous administration. Concomitant food intake does not affect the absorption of the drug when administered orally. Peak plasma concentration is reached 0.5–1.5 hours after administration. Plasma concentration is proportional to the dose. Steady-state concentrations of 90% are reached on the 4th–5th day with once-daily dosing or on the second day of treatment when a loading dose twice the usual daily dose is administered on the first day.

Distribution.

The volume of distribution is approximately equal to the total body fluid volume. Plasma protein binding is low (11–12%).

Fluconazole penetrates well into all studied body fluids. Fluconazole levels in saliva and sputum are similar to plasma concentrations. In patients with fungal meningitis, the concentration of fluconazole in cerebrospinal fluid reaches 80% of the plasma concentration.

High concentrations of fluconazole in the skin, exceeding serum levels, are achieved in the stratum corneum, epidermis, dermis, and sweat. Fluconazole accumulates in the stratum corneum.

When administered at a dose of 50 mg once daily, the concentration of fluconazole after 12 days of treatment was 73 μg/g, and 7 days after the end of treatment, the concentration was still 5.8 μg/g. When administered at a dose of 150 mg once weekly, the concentration of fluconazole on the 7th day of treatment was 23.4 μg/g; 7 days after the next dose, the concentration was still 7.1 μg/g.

The concentration of fluconazole in the nails after 4 months of once-weekly 150 mg dosing was 4.05 μg/g in healthy volunteers and 1.8 μg/g in patients with nail disorders; Fluconazole was detected in nail samples 6 months after completion of therapy.

Biotransformation.

Fluconazole is metabolized to a minor extent. Following administration of a dose labeled with radioactive isotopes, only 11% of fluconazole is excreted in the urine in a metabolized form. Fluconazole is a moderate inhibitor of the CYP2C9 and CYP3A4 isoenzymes, as well as a potent inhibitor of the CYP2C19 isoenzyme.

Elimination.

The half-life of fluconazole in plasma is approximately 30 hours. Most of the drug is excreted by the kidneys, with 80% of the administered dose appearing in the urine unchanged. The clearance of fluconazole is proportional to creatinine clearance. No circulating metabolites have been detected.

The drug’s long half-life in plasma allows for a single-dose regimen in the treatment of vaginal candidiasis, as well as once-weekly dosing for other indications.

Pharmacokinetics in Patients with Impaired Renal Function.

In patients with severe renal insufficiency (GFR < 20 mL/min), the half-life increases from 30 to 98 hours, requiring a dose reduction. Fluconazole is removed by hemodialysis and, to a lesser extent, by peritoneal dialysis. A 3-hour hemodialysis session reduces the plasma concentration of fluconazole by approximately 50%.

Pharmacokinetics during lactation.

Plasma and breast milk concentrations of fluconazole over 48 hours following a single 150-mg dose were evaluated in a pharmacokinetic study involving ten lactating women who had temporarily or permanently stopped breastfeeding their infants. The average concentration of fluconazole in breast milk was approximately 98% of that observed in the mother’s plasma. At 5.2 hours after dosing, the mean peak concentration in breast milk was 2.61 mg/L. The daily dose of fluconazole received by an infant through breast milk (assuming an average milk intake of 150 mL/kg/day), calculated based on the average peak concentration in milk of 0.39 mg/kg/day, is approximately 40% of the dose recommended for newborns (aged < 2 weeks) or 13% of the dose recommended for infants for the treatment of mucosal candidiasis.

Pharmacokinetics in children.

Pharmacokinetic parameters in children were evaluated in 5 studies: 2 single-dose studies, 2 multiple-dose studies, and one study involving preterm newborns.

Following administration of 2–8 mg/kg of fluconazole to children aged 9 months to 15 years, an AUC of approximately 38 μg·h/mL per 1 mg/kg dose was observed. With multiple dosing, the mean plasma half-life of fluconazole ranged from 15 to 18 hours, and the volume of distribution was approximately 880 mL/kg. A longer half-life of fluconazole in plasma was approximately 24 hours and was observed following a single dose. This value is comparable to the plasma half-life of fluconazole following a single intravenous dose of 3 mg/kg in children aged 11 days to 11 months. The volume of distribution in this age group was approximately 950 mL/kg.

Experience with fluconazole for the treatment of newborns is limited to pharmacokinetic studies in 12 preterm infants with a gestational age of approximately 28 weeks. The mean age of the infants at the time of the first dose was 24 hours (range 9–36 hours), and the mean birth weight was 0.9 kg (range 0.75–1.10 kg). A maximum of 5 intravenous injections of fluconazole at a dose of 6 mg/kg were administered every 72 hours. The mean half-life was 74 hours (44–185) on the first day, then decreased to 53 hours (30–131) on day 7 and to 47 (27–68) on day 13. The area under the curve (μg·h/mL) was 271 (173–385) on day 1, increased to 490 (292–734) on day 7, then decreased to 360 (167–566) on day 13. The volume of distribution (mL/kg) was 1,183 (1,070–1,470) on day 1, increased to 1,184 (510–2,130) on day 7 and to 1,328 (1,040–1,680) on day 13, respectively.

Pharmacokinetics in Elderly Patients.

In a study involving 22 patients (aged 65 years and older), fluconazole was administered orally at a dose of 50 mg. Ten of the participants were concurrently taking diuretics. Cmax was 1.54 μg/mL and was reached within 1.3 hours after administration of fluconazole. The mean AUC was 76.4 ± 20.3 μg·h/mL. The mean half-life was 46.2 hours. These pharmacokinetic parameters are higher than those observed in younger healthy volunteers. Concomitant use of diuretics had no significant effect on Cmax or AUC. In addition, creatinine clearance (74 mL/min), the percentage of fluconazole excreted unchanged in urine (0–24 hours, 22%), and the renal clearance of fluconazole (0.124 mL/min/kg) in patients in this age group were lower than the corresponding values in younger volunteers. Therefore, changes in pharmacokinetics in elderly patients appear to depend on renal function parameters.

Indications

Fucis® is indicated for the treatment of the following fungal infections in adults (see the “Pharmacodynamics” section):

  • cryptococcal meningitis (see the “Special Considerations for Use” section);
  • coccidioidomycosis (see the “Special Considerations for Use” section);
  • invasive candidiasis;
  • mucosal candidiasis, including oropharyngeal candidiasis and esophageal candidiasis; candiduria, chronic candidiasis of the skin and mucous membranes;
  • chronic atrophic oral candidiasis (candidiasis caused by the use of dentures) when oral hygiene or local therapy is ineffective;
  • vaginal candidiasis, whether acute or recurrent, when local therapy is not appropriate;
  • candidal balanitis, when local therapy is not appropriate;
  • dermatomycoses, including tinea pedis, tinea corporis, and tinea cruris; pityriasis versicolor and candidal skin infections, when systemic therapy is indicated;
  • dermatophyte onychomycosis, when the use of other medications is not appropriate.

Fucis® is indicated for the prevention of the following conditions in adults:

  • recurrence of cryptococcal meningitis in patients at high risk of developing it;
  • recurrence of oropharyngeal or esophageal candidiasis in HIV-positive patients at high risk of developing it;
  • to reduce the frequency of recurrent vaginal candidiasis (4 or more episodes per year);
  • prevention of candidal infections in patients with prolonged neutropenia (e.g., patients with malignant blood disorders receiving chemotherapy, or patients undergoing hematopoietic stem cell transplantation) (see the section “Pharmacological Properties. Pharmacodynamics”).

Children.

Fucis® is indicated in children for the treatment of candidiasis of the mucous membranes (oropharyngeal candidiasis, esophageal candidiasis), invasive candidiasis, cryptococcal meningitis, and for the prevention of candidal infections in immunocompromised patients. The drug may be used as maintenance therapy to prevent recurrence of cryptococcal meningitis in children at high risk of developing it (see the “Special Considerations for Use” section).

The drug in tablet form may be administered to this patient population when children are able to safely swallow a tablet, which is usually possible starting at age 5.

Treatment with Fucis® may be initiated before the results of culture and other laboratory tests are available; however, once the results are received, antimicrobial therapy should be adjusted accordingly.

Contraindications

  • Hypersensitivity to fluconazole, other azole compounds, or to any of the drug’s excipients.
  • Concomitant use of fluconazole and terfenadine in patients receiving repeated doses of fluconazole at 400 mg/day or higher (based on the results of a repeated-dose interaction study).
  • Concomitant use of fluconazole with other drugs that prolong the QT interval and are metabolized by CYP3A4 (e.g., cisapride, astemizole, pimozide, quinidine, and erythromycin); see the sections “Special Considerations for Use” and “Interactions with Other Medications and Other Types of Interactions.”

Interactions with Other Medications and Other Types of Interactions

The concomitant use of fluconazole and the drugs listed below is contraindicated.

Cisapride: Adverse cardiac reactions, including “pirouette”-type paroxysmal ventricular tachycardia, have been reported in patients receiving concomitant fluconazole and cisapride. Concomitant administration of 200 mg of fluconazole once daily and 20 mg of cisapride four times daily resulted in a significant increase in cisapride plasma levels and QT interval prolongation. Concomitant use of fluconazole and cisapride is contraindicated (see “Contraindications”).

Terfenadine: Due to cases of severe cardiac arrhythmias caused by QTc prolongation, in patients taking azole antifungal agents concomitantly with terfenadine, drug interaction studies were conducted. No QTc prolongation was observed with fluconazole at a dose of 200 mg per day. Administration of fluconazole at doses of 400 mg per day or higher significantly increases plasma levels of terfenadine when these drugs are used concomitantly. Concomitant use of fluconazole at doses of 400 mg or higher with terfenadine is contraindicated (see the “Contraindications” section). When fluconazole is administered at doses below 400 mg per day concomitantly with terfenadine, the patient’s condition should be closely monitored.

Astemizole: Concomitant use of fluconazole and astemizole may reduce the clearance of astemizole. The resulting increase in astemizole plasma concentrations may lead to QT interval prolongation and, in rare cases, to paroxysmal ventricular tachycardia of the “pirouette” type. Concomitant use of fluconazole and astemizole is contraindicated (see the “Contraindications” section).

Pimozide: Concomitant use of fluconazole with pimozide may result in inhibition of pimozide metabolism, although no relevant in vitro or in vivo studies have been conducted. Elevated plasma concentrations of pimozide may lead to QT interval prolongation and, in rare cases, to paroxysmal ventricular tachycardia of the “pirouette” type. Concomitant use of fluconazole with pimozide is contraindicated (see the “Contraindications” section).

Quinidine: Concomitant use of fluconazole and quinidine may result in inhibition of quinidine metabolism, although no relevant in vitro or in vivo studies have been conducted. The use of quinidine has been associated with QT interval prolongation and, in rare cases, paroxysmal ventricular tachycardia of the “pirouette” type. Concomitant use of fluconazole with quinidine is contraindicated (see the “Contraindications” section).

Erythromycin: Concomitant use of fluconazole with erythromycin may increase the risk of cardiotoxicity (QT interval prolongation and paroxysmal ventricular tachycardia of the “pirouette” type) and, consequently, sudden coronary death. Concomitant use of fluconazole and erythromycin is contraindicated (see the “Contraindications” section).

Concomitant use of fluconazole and the drugs listed below is not recommended.

Halofantrine: Fluconazole may cause an increase in halofantrine plasma concentrations due to CYP3A4 inhibition. Concomitant use of these drugs may potentially increase the risk of cardiotoxicity (QT interval prolongation, paroxysmal ventricular tachycardia of the “pirouette” type) and, consequently, sudden cardiac death. The combination of these drugs should be avoided (see the “Special Considerations for Use” section).

Caution is advised when fluconazole is used concomitantly with the drugs listed below.

Amiodarone: Concomitant use of fluconazole with amiodarone may lead to QT interval prolongation. If concomitant use of fluconazole and amiodarone is necessary, caution is advised, especially when fluconazole is administered at high doses (800 mg).

Concomitant use of fluconazole and the medications listed below requires caution and dose adjustment.

Effects of Other Medications on Fluconazole.

Concomitant food intake, cimetidine, antacids, and total-body radiation therapy (during bone marrow transplantation) have no clinically significant effect on the absorption of fluconazole when administered orally.

Rifampicin: Concomitant use of fluconazole and rifampicin resulted in a 25% decrease in AUC and a 20% reduction in the half-life of fluconazole. Therefore, for patients taking rifampicin, consideration should be given to increasing the dose of fluconazole.

Hydrochlorothiazide: In a pharmacokinetic interaction study, the concomitant repeated administration of hydrochlorothiazide to healthy volunteers receiving fluconazole increased the plasma concentration of fluconazole by 40%. These interaction parameters do not require changes to the fluconazole dosing regimen for patients who are concurrently receiving diuretics.

Effect of fluconazole on other drugs.

Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4. Fluconazole is a potent inhibitor of CYP2C19. In addition to the observed/documented interactions described below, there is a risk of increased plasma concentrations of other compounds metabolized by CYP2C9, CYP2C19, and CYP3A4. Therefore, such drug combinations should be used with caution; patients should be closely monitored. The inhibitory effect of fluconazole on these enzymes persists for 4–5 days after administration due to its long half-life (see the “Contraindications” section).

Alfentanil: Concomitant administration of 400 mg of fluconazole and 20 μg/kg of alfentanil intravenously is associated with a twofold increase in the AUC10 (possibly due to CYP3A4 inhibition). This necessitates a dose adjustment of alfentanil.

Amitriptyline, nortriptyline: Fluconazole potentiates the effects of amitriptyline and nortriptyline. It is recommended to measure the concentrations of 5-nortriptyline and/or S-amitriptyline at the start of combination therapy and 1 week after its initiation. If necessary, the dose of amitriptyline or nortriptyline should be adjusted.

Amphotericin B: Concomitant administration of fluconazole and amphotericin B to infected mice with normal immunity and infected mice with compromised immunity yielded the following results: a slight additive antifungal effect in systemic Candida albicans infection, no interaction in intracranial Cryptococcus neoformans infection, and antagonism between the two drugs in systemic Aspergillus fumigatus infection. The clinical significance of these results is unknown.

Anticoagulants: As with other azole antifungals, cases of bleeding (hematoma, epistaxis, gastrointestinal bleeding, hematuria, and melena) against a background of prolonged prothrombin time. With the concomitant use of fluconazole and warfarin, a twofold increase in prothrombin time was observed, presumably due to inhibition of warfarin metabolism via CYP2C9. Prothrombin time should be carefully monitored in patients who are concurrently taking coumarin anticoagulants or indandione. Adjustment of the anticoagulant dose may be necessary.

Short-acting benzodiazepines, such as midazolam and triazolam: administration of fluconazole following oral administration of midazolam resulted in a significant increase in midazolam concentrations and an intensification of psychomotor effects. Concomitant administration of 200 mg of fluconazole and 7.5 mg of midazolam orally resulted in a 3.7-fold and 2.2-fold increase in AUC and half-life, respectively. Administration of 200 mg/day of fluconazole and 0.25 mg of triazolam orally resulted in a 4.4-fold and 2.3-fold increase in the AUC and half-life of triazolam, respectively. When fluconazole and triazolam were administered concomitantly, potentiation and prolongation of triazolam’s effects were observed.

If a patient undergoing treatment with fluconazole requires concomitant therapy with benzodiazepines, the dose of the benzodiazepines should be reduced, and the patient’s condition should be closely monitored.

Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and causes a 30% increase in serum carbamazepine levels. There is a risk of carbamazepine toxicity. It may be necessary to adjust the carbamazepine dose based on its serum concentration and the drug’s effects.

Calcium channel blockers: Some calcium channel blockers (nifedipine, isradipine, amlodipine, verapamil, and felodipine) are metabolized by the CYP3A4 enzyme. Fluconazole may potentially increase the systemic exposure of calcium channel blockers. Close monitoring for the development of adverse reactions is recommended.

Celecoxib: When fluconazole (200 mg daily) and celecoxib (200 mg) were administered concomitantly, the Cmax and AUC of celecoxib increased by 68% and 134%, respectively. When celecoxib and fluconazole are used concomitantly, it may be necessary to reduce the celecoxib dose by half.

Cyclophosphamide: Concomitant use of cyclophosphamide and fluconazole leads to increased levels of bilirubin and creatinine in serum. These drugs may be used concomitantly, taking into account the potential risk of increased serum bilirubin and creatinine concentrations.

Fentanyl: One fatal case of fentanyl intoxication has been reported due to a possible interaction between fentanyl and fluconazole. Fluconazole significantly delays the elimination of fentanyl. Increased fentanyl concentrations may lead to respiratory depression; therefore, the patient’s condition should be closely monitored. A dose adjustment of fentanyl may be necessary.

HMG-CoA reductase inhibitors: Concomitant use of fluconazole with HMG-CoA reductase inhibitors metabolized by CYP3A4 (atorvastatin and simvastatin), or HMG-CoA reductase inhibitors metabolized by CYP2C9 (fluvastatin), increases the risk of myopathy and rhabdomyolysis. If concomitant use of these drugs is necessary, the patient should be closely monitored for symptoms of myopathy and rhabdomyolysis, and creatine kinase levels should be monitored. If creatine kinase levels rise significantly, or if myopathy or rhabdomyolysis is suspected or confirmed, treatment with HMG-CoA reductase inhibitors should be discontinued.

Ibrutinib: Moderate CYP3A4 inhibitors, such as fluconazole, increase the plasma concentration of ibrutinib and may increase the risk of toxicity. If the drug combination cannot be avoided, the dose of ibrutinib should be reduced to 280 mg once daily to allow continued use of the inhibitor, and close clinical monitoring should be ensured.

Ivacaftor: Concomitant use of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, increased ivacaftor exposure 3-fold and hydroxymethylivacaftor (M1) exposure 1.9-fold. Patients who are also taking moderate CYP3A inhibitors, such as fluconazole and erythromycin, are advised to reduce the dose of ivacaftor to 150 mg once daily.

Olaparib: Moderate CYP3A4 inhibitors, such as fluconazole, increase the plasma concentration of olaparib; concomitant use is not recommended. If this combination cannot be avoided, the dose of olaparib should be reduced to 200 mg twice daily.

Immunosuppressants (e.g., cyclosporine, everolimus, sirolimus, and tacrolimus).

Cyclosporine: Fluconazole significantly increases the concentration and AUC of cyclosporine. When fluconazole 200 mg/day was coadministered with cyclosporine 2.7 mg/kg/day, the AUC of cyclosporine increased 1.8-fold. These drugs may be used concomitantly provided that the cyclosporine dose is reduced based on its concentration.

Everolimus: Fluconazole may increase serum concentrations of everolimus by inhibiting CYP3A4.

Sirolimus: Fluconazole increases sirolimus plasma concentrations, presumably by inhibiting sirolimus metabolism by CYP3A4 and P-glycoprotein. These drugs may be used concomitantly provided that the sirolimus dose is adjusted based on serum concentrations and clinical response.

Tacrolimus: Fluconazole may increase serum tacrolimus concentrations up to 5-fold when administered orally due to inhibition of tacrolimus metabolism by CYP3A4 in the intestine. No significant changes in pharmacokinetics were observed with intravenous tacrolimus. Elevated tacrolimus levels are associated with nephrotoxicity. The dose of tacrolimus for oral administration should be reduced depending on the tacrolimus concentration.

Losartan: Fluconazole inhibits the conversion of losartan to its active metabolite (E-31 74), which accounts for most of the angiotensin II receptor antagonism during losartan administration. It is recommended to monitor blood pressure in patients on a regular basis.

Methadone: Fluconazole may increase serum methadone concentrations. When methadone and fluconazole are administered concomitantly, adjustment of the methadone dose may be necessary.

Nonsteroidal anti-inflammatory drugs (NSAIDs): When co-administered with fluconazole, the Cmax and AUC of flurbiprofen increased by 23% and 81%, respectively, compared with the corresponding values when flurbiprofen was administered alone. Similarly, when fluconazole was co-administered with racemic ibuprofen (400 mg), the Cmax and AUC of the pharmacologically active isomer S-(+)-ibuprofen increased by 15% and 82%, respectively, compared with the corresponding values when racemic ibuprofen was administered alone.

Fluconazole has the potential to increase the systemic exposure of other NSAIDs metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). It is recommended to periodically monitor for adverse reactions and toxic effects associated with NSAIDs. Adjustment of the NSAID dose may be necessary.

Phenytoin: Fluconazole inhibits the hepatic metabolism of phenytoin. Concomitant multiple administration of 200 mg of fluconazole and 250 mg of phenytoin intravenously results in a 75% increase in phenytoin AUC24 and a 128% increase in Cmin. When these drugs are used concomitantly, serum phenytoin concentrations should be monitored to prevent the development of phenytoin toxicity.

Prednisone: A case has been reported in which a patient who had undergone a liver transplant developed acute adrenal insufficiency while taking prednisone; this occurred after discontinuation of a three-month course of fluconazole therapy. Discontinuation of fluconazole likely caused an increase in CYP3A4 activity, leading to accelerated metabolism of prednisone. Patients receiving long-term concomitant therapy with fluconazole and prednisone should be closely monitored to prevent the development of adrenal insufficiency following discontinuation of fluconazole.

Rifabutin: Fluconazole increases rifabutin serum concentrations, leading to an increase in rifabutin AUC of up to 80%. Cases of uveitis have been reported with the concomitant use of fluconazole and rifabutin. When using this combination of drugs, the symptoms of rifabutin toxicity should be monitored.

Saquinavir: Fluconazole increases the AUC and Cmax of saquinavir by approximately 50% and 55%, respectively, due to inhibition of saquinavir metabolism in the liver by the CYP3A4 enzyme and inhibition of P-glycoprotein. Interactions between fluconazole and saquinavir/ritonavir have not been studied; therefore, they may be more pronounced. A dose adjustment of saquinavir may be necessary.

Sulfonylureas: Concomitant use of fluconazole with oral sulfonylureas (chlorpropamide, glibenclamide, glipizide, and tolbutamide) has resulted in a prolongation of their half-lives. Frequent monitoring of blood glucose levels is recommended, and the dose of sulfonylureas should be reduced accordingly when used concomitantly with fluconazole.

Theophylline: Administration of 200 mg of fluconazole daily for 14 days resulted in an 18% decrease in the mean plasma clearance of theophylline. Patients receiving high doses of theophylline or who are at increased risk of theophylline toxicity for other reasons should be monitored for signs of theophylline toxicity. Therapy should be adjusted if signs of toxicity appear.

Tofacitinib: The effect of tofacitinib is enhanced when used concomitantly with drugs that cause moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). Therefore, it is recommended to reduce the dose of tofacitinib to 5 mg once daily when used in combination with these drugs.

Tolvaptan: The exposure to tolvaptan (a CYP3A4 substrate) increases significantly (200% AUC; 80% Cmax) when coadministered with fluconazole (a moderate CYP3A4 inhibitor), and, accordingly, the risk of adverse reactions such as increased diuresis, dehydration, and acute renal failure increases. When used concomitantly, the dose of tolvaptan should be reduced in accordance with its prescribing information, and the patient should be monitored for adverse reactions.

Periwinkle alkaloids: Fluconazole may, presumably through CYP3A4 inhibition, cause an increase in the plasma concentration of periwinkle alkaloids (e.g., vincristine and vinblastine), leading to the development of neurotoxic effects.

Vitamin A: It has been reported that in a patient who was taking both transretinoic acid (the acid form of vitamin A) and fluconazole, experienced CNS adverse reactions in the form of pseudotumor cerebri, which resolved after discontinuation of fluconazole. These medications may be used concomitantly, but the risk of CNS adverse reactions should be kept in mind.

Voriconazole (an inhibitor of CYP2C9, CYP2C19, and CYP3A4): Concomitant use of oral voriconazole (400 mg every 12 hours for 1 day, followed by 200 mg every 12 hours for 2.5 days) and oral fluconazole (400 mg on the first day, followed by 200 mg every 24 hours for 4 days) resulted in an increase in the Cmax and AUCτ of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. It is unknown whether reducing the dose and/or frequency of voriconazole or fluconazole administration eliminates this effect. When voriconazole is administered following fluconazole, patients should be monitored for the development of adverse effects associated with voriconazole.

Zidovudine: Fluconazole increases the Cmax and AUC of zidovudine by 84% and 74%, respectively, due to a reduction in zidovudine clearance of approximately 45% following oral administration. The half-life of zidovudine was also prolonged by approximately 128% following co-administration of fluconazole and zidovudine. Patients receiving this combination of medications should be monitored for the development of adverse reactions associated with zidovudine use. Consideration should be given to reducing the zidovudine dose.

Azithromycin: No significant pharmacokinetic interactions were observed following the simultaneous single oral administration of azithromycin and fluconazole at doses of 1,200 mg and 800 mg, respectively.

Oral contraceptives: When fluconazole was administered at a dose of 50 mg, there was no effect on hormone levels, whereas with a daily dose of 200 mg of fluconazole, a 40% increase in the AUC of ethinyl estradiol and a 24% increase in the AUC of levonorgestrel were observed. This suggests that repeated administration of fluconazole at these doses is unlikely to affect the efficacy of combined oral contraceptives.

Ivacaftor: Concomitant use with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) enhancer, increases the exposure to ivacaftor 3-fold, and that of hydroxymethyl-ivacaftor (M1) by 1.9 times. For patients who are also taking moderate CYP3A inhibitors, such as fluconazole and erythromycin, a dose reduction of ivacaftor to 150 mg once daily is recommended.

Special Considerations for Use

Dermatophytosis. It is known that when fluconazole is used to treat dermatophytosis in children, its efficacy does not exceed that of griseofulvin, and the overall efficacy rate is less than 20%. Therefore, fluconazole should not be used to treat dermatophytosis.

Cryptococcosis. There is insufficient evidence of fluconazole’s efficacy for treating cryptococcosis in other sites (e.g., pulmonary cryptococcosis and cutaneous cryptococcosis); therefore, there are no recommendations regarding the dosing regimen for treating such conditions.

Deep endemic mycoses. There is insufficient evidence of the efficacy of fluconazole for the treatment of other forms of endemic mycoses, such as paracoccidioidomycosis, histoplasmosis, and cutaneous-lymphatic sporotrichosis; therefore, there are no dosage recommendations for the treatment of such conditions.

Renal system. The drug should be used with caution in patients with impaired renal function (see the “Dosage and Administration” section).

Adrenal insufficiency. Ketoconazole is known to cause adrenal insufficiency, and this may also apply to fluconazole, although it is rarely observed. Adrenal insufficiency associated with concomitant treatment with prednisone is described in the subsection “Effects of Fluconazole on Other Medications” in the section “Interactions with Other Medications and Other Types of Interactions.”

Hepatobiliary system. The drug should be used with caution in patients with impaired liver function. The use of fluconazole has been associated with rare cases of severe hepatotoxicity, including fatal cases, primarily in patients with severe underlying medical conditions. In cases where the development of hepatotoxicity was associated with fluconazole use, no clear correlation was observed with the total daily dose of the drug, duration of therapy, gender, or age of the patient. Hepatotoxicity caused by fluconazole is usually reversible, and its symptoms resolve after discontinuation of therapy.

Patients who exhibit abnormal liver function test results while taking fluconazole should be closely monitored for the development of more severe liver damage.

Patients should be informed of symptoms that may indicate serious liver damage (severe asthenia, anorexia, persistent nausea, vomiting, and jaundice). In such cases, fluconazole treatment should be discontinued immediately, and a physician should be consulted.

Cardiovascular system. Some azoles, including fluconazole, are associated with QT interval prolongation on the electrocardiogram. Fluconazole causes QT interval prolongation by inhibiting the ion current through inward-rectifying potassium channels (Ikr). QT interval prolongation caused by other medications (such as amiodarone) may be exacerbated by inhibition of the cytochrome P450 CYP3A4 enzyme. Very rare cases of QT interval prolongation and paroxysmal ventricular tachycardia of the “pirouette” type have been reported with fluconazole use. These reports involved patients with severe illnesses and a combination of multiple risk factors, such as structural heart disease, electrolyte imbalances, and concomitant use of other medications that affect the QT interval. Patients with hypokalemia and severe heart failure are at increased risk of life-threatening ventricular arrhythmias and paroxysmal ventricular tachycardia of the “pirouette” type.

Fluconazole should be used with caution in patients at risk of developing arrhythmias. Concomitant use with drugs that prolong the QTc interval and are metabolized by the CYP3A4 enzyme of cytochrome P450 is contraindicated (see the sections “Contraindications” and “Drug Interactions and Other Interactions”).

Halofantrine. Halofantrine is a substrate of CYP3A4 and prolongs the QTc interval when administered at recommended therapeutic doses. Concomitant use of halofantrine and fluconazole is not recommended (see the “Interactions with Other Medications and Other Types of Interactions” section).

Dermatological reactions. Rare cases of exfoliative skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported during treatment with fluconazole. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. Patients with AIDS are more prone to developing severe skin reactions when taking many medications. If a patient with a superficial fungal infection develops a rash that may be associated with fluconazole use, further administration of the drug should be discontinued. If a patient with an invasive/systemic fungal infection develops a skin rash, the patient’s condition should be closely monitored; if bullous rashes or erythema multiforme develop, fluconazole should be discontinued.

Hypersensitivity. In rare cases, anaphylactic reactions have been reported (see the “Contraindications” section).

Cytochrome P450. Fluconazole is a moderate inhibitor of the CYP2C9 and CYP3A4 enzymes. Fluconazole is also a moderate inhibitor of the CYP2C19 enzyme. Patients receiving concomitant treatment with fluconazole and drugs with a narrow therapeutic index that are metabolized by CYP2C9, CYP2C19, and CYP3A4 (see the “Drug Interactions and Other Interactions” section).

Terfenadine. Patients should be closely monitored when terfenadine is used concomitantly with fluconazole at a dose of less than 400 mg per day (see the “Contraindications” and “Interactions with Other Medications and Other Types of Interactions” sections).

Candidiasis. Studies have shown an increase in the prevalence of Candida species other than C. albicans. These species are often inherently resistant (e.g., C. krusei and C. auris) or exhibit reduced susceptibility to fluconazole (C. glabrata). Such infections may require alternative antifungal therapy due to treatment failure. Therefore, it is recommended to consider the prevalence of fluconazole resistance among various Candida species.

Inactive ingredients.

This medication contains lactose. If a patient has been diagnosed with an intolerance to certain sugars, they should consult a doctor before taking this medication.

Use during pregnancy or breastfeeding.

Pregnancy.

According to an observational study, there is an increased risk of spontaneous abortion in women who received fluconazole during the first trimester of pregnancy.

Numerous congenital anomalies have been reported in newborns (including brachycephaly, auricular dysplasia, excessive enlargement of the anterior fontanelle, hip deformity, and humeroradial synostosis) whose mothers took high doses of fluconazole (400–800 mg/day) for at least three or more months to treat coccidioidomycosis. A causal relationship between fluconazole use and these cases has not been established.

Animal studies have demonstrated reproductive toxicity.

Standard doses of fluconazole and short-term courses of fluconazole therapy should not be used during pregnancy unless absolutely necessary.

High doses of fluconazole and/or prolonged courses of fluconazole therapy should not be used during pregnancy, except for the treatment of life-threatening infections.

Breastfeeding.

Fluconazole is excreted into breast milk and reaches concentrations similar to those in blood plasma (see the “Pharmacokinetics” section). Breastfeeding may be continued after a single administration of the usual dose of fluconazole, which is 150 mg.

Breastfeeding is not recommended with repeated use of fluconazole or when high doses of fluconazole are used.

The benefits of breastfeeding for the infant’s development and health should be weighed against the mother’s clinical need for Fucis® and any potential adverse effects of Fucis® or the mother’s underlying condition on the breastfed infant.

Fertility.

Fluconazole did not affect fertility in male and female rats.

Effect on reaction time when operating motor vehicles or other machinery.

No studies have been conducted on the effect of fluconazole on the ability to drive or operate machinery.

Patients should be informed of the possibility of dizziness or seizures (see the “Adverse Reactions” section) while taking this medication. If such symptoms develop, driving or operating machinery is not recommended.

Dosage and Administration

The drug is administered orally. Administration is not affected by food intake.

The daily dose of fluconazole depends on the type and severity of the fungal infection. If repeated administration is necessary, treatment of infections should be continued until clinical and laboratory signs of fungal infection have resolved. Insufficient duration of treatment may lead to recurrence of the active infection.

Adults.

Cryptococcosis.

  • Treatment of cryptococcal meningitis: the loading dose is 400 mg on the first day. The maintenance dose is 200–400 mg/day. The duration of treatment is usually at least 6–8 weeks. For life-threatening infections, the daily dose may be increased to 800 mg.
  • Maintenance therapy to prevent recurrence of cryptococcal meningitis in patients at high risk of developing the condition: the recommended dose is 200 mg/day for an indefinite period.

Coccidioidomycosis. The recommended dose is 200–400 mg/day. The duration of treatment is 11–24 months or longer, depending on the patient’s condition. For the treatment of certain forms of infection, particularly meningitis, a dose of 800 mg/day may be appropriate.

Invasive candidiasis. The loading dose is 800 mg on the first day. The maintenance dose is 400 mg/day. The usual recommended duration of treatment for candidemia is 2 weeks after the first negative blood culture results and the resolution of signs and symptoms of candidemia.

Mucosal candidiasis.

  • Oropharyngeal candidiasis: the loading dose is 200–400 mg on the first day; the maintenance dose is 100–200 mg/day. The duration of treatment is 7–21 days (until remission is achieved), but may be extended for patients with severe immunodeficiency.
  • Esophageal candidiasis: the loading dose is 200–400 mg on the first day, and the maintenance dose is 100–200 mg/day. The duration of treatment is 14–30 days (until remission is achieved), but may be extended for patients with severe immunodeficiency.
  • Candiduria: The recommended dose is 200–400 mg/day for 7–21 days. For patients with severe immunodeficiency, the duration of treatment may be extended.
  • Chronic atrophic candidiasis: The recommended dose is 50 mg/day for 14 days.
  • Chronic candidiasis of the skin and mucous membranes: The recommended dose is 50–100 mg/day. The duration of treatment is up to 28 days, but may be extended depending on the severity and type of infection or in cases of immunosuppression.

Prevention of recurrence of candidiasis of the mucous membranes in HIV-positive patients at high risk of developing the condition.

  • Oropharyngeal candidiasis, esophageal candidiasis: the recommended dose is 100–200 mg/day or 200 mg 3 times a week. The duration of treatment is unlimited for immunocompromised patients.

Prevention of candidal infections in patients with prolonged neutropenia. The recommended dose is 200–400 mg. Treatment should be initiated several days before the expected onset of neutropenia and continued for 7 days after the neutrophil count rises above 1,000/mm³.

Genital candidiasis.

  • Acute vaginal candidiasis, candidal balanitis: the recommended dose is 150 mg as a single dose.
  • Treatment and prevention of recurrent vaginal candidiasis (4 or more recurrences per year): the recommended dose is 150 mg once every 3 days. A total of 3 doses are required (on days 1, 4, and 7). After that, a maintenance dose of 150 mg should be taken once a week for 6 months.

Dermatomycoses.

  • Athlete’s foot, tinea corporis, tinea cruris, and candidal skin infections: the recommended dose is 150 mg once a week or 50 mg once daily. The duration of treatment is 2–4 weeks. Treatment of athlete’s foot may last up to 6 weeks.
  • Pityriasis versicolor: The recommended dose is 300–400 mg once a week for 1–3 weeks or 50 mg daily for 2–4 weeks.
  • Dermatophyte onychomycosis: The recommended dose is 150 mg once a week. Treatment should continue until a healthy nail has grown in place of the infected one. It usually takes 3–6 months for healthy fingernails to grow back and 6–12 months for healthy toenails to grow back. However, nail growth rates may vary among patients and depend on age. After successful treatment of long-standing chronic infections, the shape of the nail may sometimes remain altered.

Elderly patients.

The dose should be adjusted based on renal function (see below).

Patients with renal impairment.

Fluconazole is excreted primarily in the urine in an unchanged form. No dose adjustment of fluconazole is required for a single dose. For patients (including children) with impaired renal function who require multiple doses, an initial dose of 50–400 mg should be administered on the first day of treatment, depending on the indication. Thereafter, the daily dose (depending on the indication) should be calculated according to the table below:

Creatinine clearance (mL/min) Percentage of the recommended dose
> 50 100%
≤ 50 (without hemodialysis) 50%
Hemodialysis 100% after each hemodialysis session

Patients undergoing regular hemodialysis should receive 100% of the recommended dose after each hemodialysis session. On days when hemodialysis is not performed, the patient should receive a dose adjusted based on creatinine clearance.

Patients with hepatic impairment.

Fluconazole should be used with caution in patients with hepatic impairment, as there is insufficient information regarding the use of fluconazole in this patient population (see the “Special Considerations” and “Adverse Reactions” sections).

Children.

The tablet form of this medication may be used in this patient population when children are able to safely swallow a tablet, which is usually possible starting at age 5.

Do not exceed the maximum daily dose of 400 mg.

As with similar infections in adults, the duration of treatment depends on the clinical and mycological response. Administer the medication once daily.

Dosage recommendations for children with renal impairment are provided above. The pharmacokinetics of fluconazole have not been studied in children with renal insufficiency.

Children 12 years of age and older.

Depending on body weight and pubertal development, the physician should determine which dose (adult or pediatric) is optimal for the patient. Clinical data indicate that the clearance of fluconazole is higher in children than in adults. Administering doses of 100, 200, or 400 mg to adults and doses of 3, 6, or 12 mg/kg to children results in comparable systemic exposure.

The efficacy and safety of fluconazole for the treatment of genital candidiasis in children have not been established. If there is an urgent need to administer the drug to adolescents (ages 12 to 17), the usual adult doses should be used.

Children aged 5 to 11 years.

Mucosal candidiasis: the initial dose is 6 mg/kg/day; the maintenance dose is 3 mg/kg/day. The initial dose may be administered on the first day to achieve steady-state concentrations more rapidly.

Invasive candidiasis, cryptococcal meningitis: the dose is 6–12 mg/kg/day, depending on the severity of the disease.

Maintenance therapy to prevent recurrence of cryptococcal meningitis in children at high risk of developing the condition: the dose is 6 mg/kg/day, depending on the severity of the disease.

Prevention of candidiasis in immunocompromised patients: the dose is 3–12 mg/kg/day, depending on the severity and duration of induced neutropenia (see dosages for adults).

Children.

The drug in tablet form may be administered to this patient population when children are able to safely swallow a tablet, which is usually possible starting at age 5.

Overdose

Symptoms: hallucinations and paranoid behavior.

Treatment: symptomatic (including gastric lavage and supportive care). Fluconazole is excreted primarily in the urine; therefore, forced diuresis may accelerate the elimination of the drug. A 3-hour hemodialysis session reduces plasma fluconazole levels by approximately 50%.

Side Effects

Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of fluconazole has been reported (see the “Special Precautions for Use” section).

The following adverse reactions were reported most frequently (≥1/100 to <1/10): headache, abdominal pain, diarrhea, nausea, vomiting, elevated levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum alkaline phosphatase, and rash

The following classification is used to assess the frequency of adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), frequency unknown (cannot be estimated from the available data).

Blood and lymphatic system disorders.

Uncommon: anemia.

Rare: agranulocytosis, leukopenia, neutropenia, thrombocytopenia.

Immune system disorders.

Rare: anaphylaxis.

Metabolism and nutrition.

Uncommon: decreased appetite.

Rare: hypertriglyceridemia, hypercholesterolemia, hypokalemia.

Psychiatric disorders.

Uncommon: insomnia, drowsiness.

Nervous system disorders.

Common: headache.

Uncommon: convulsions, dizziness, paresthesia, taste disturbances.

Rare: tremor.

Ear and balance disorders.

Uncommon: vertigo.

Cardiac disorders.

Rare: paroxysmal ventricular tachycardia of the “pirouette” type, QT interval prolongation (see the “Special Considerations for Use” section).

Gastrointestinal disorders.

Common: abdominal pain, diarrhea, nausea, vomiting.

Uncommon: constipation, dyspepsia, flatulence, dry mouth.

Hepatobiliary system.

Common: elevated levels of ALT, AST, and alkaline phosphatase in the blood (see the “Special Precautions for Use” section).

Uncommon: cholestasis, jaundice, elevated bilirubin levels (see the “Special Considerations for Use” section).

Rare: liver failure, hepatocellular necrosis, hepatitis, hepatocellular damage (see the “Special Considerations for Use” section).

Skin and subcutaneous tissue disorders.

Common: rash (see the “Special Precautions for Use” section).

Uncommon: pruritus, drug-induced dermatitis (including fixed drug eruption), urticaria, increased sweating (see the “Special Precautions for Use” section).

Rare: toxic epidermal necrolysis, Stevens–Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, angioedema, facial swelling, alopecia (see the “Special Considerations for Use” section).

Frequency unknown: drug reaction with eosinophilia and systemic symptoms (DRESS).

Musculoskeletal and connective tissue disorders.

Uncommon: myalgia.

General disorders and administration site conditions.

Uncommon: increased fatigue, malaise, asthenia, fever.

Children

The frequency and nature of adverse reactions and laboratory abnormalities in children observed during clinical trials, with the exception of genital candidiasis, are comparable to those in adults.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after the drug’s approval is an important procedure. This allows for continued monitoring of the benefit-risk profile of this drug. Healthcare professionals should report all suspected adverse reactions through the national reporting system and to the marketing authorization holder via the feedback form on the website: https://kusum.ua/pharmacovigilance/.

Shelf Life

3 years.

Storage conditions

Store at a temperature not exceeding 25 °C

Keep out of reach of children.

Packaging

50 mg tablets, No. 4 or No. 10, in a blister pack inside a cardboard box.

100 mg tablets, No. 4 or No. 10, in a blister pack inside a cardboard box.

150 mg tablets, No. 2 or No. 4, in a blister pack inside a cardboard box.

200 mg tablets, 4 or 10 per blister pack in a cardboard box.

Dispensing category

By prescription.

Manufacturer

KUSUM HEALTHCARE PVT LTD/

KUSUM HEALTHCARE PVT LTD.